Targeted Therapy of Kidney Disease with Nanoparticle Drug Delivery Materials

Overview

Journal Bioact Mater

Specialty Biomedical Engineering

Date 2024 Apr 1

PMID 38560369

Authors

Shunlai Shang

Xiangmeng Li

Haoran Wang

Yena Zhou

Keying Pang

Ping Li

Xiaomin Liu

Min Zhang

Wenge Li

Qinggang Li

Xiangmei Chen

Affiliations

Soon will be listed here.

Abstract

With the development of nanomedicine, nanomaterials have been widely used, offering specific drug delivery to target sites, minimal side effects, and significant therapeutic effects. The kidneys have filtration and reabsorption functions, with various potential target cell types and a complex structural environment, making the strategies for kidney function protection and recovery after injury complex. This also lays the foundation for the application of nanomedicine in kidney diseases. Currently, evidence in preclinical and clinical settings supports the feasibility of targeted therapy for kidney diseases using drug delivery based on nanomaterials. The prerequisite for nanomedicine in treating kidney diseases is the use of carriers with good biocompatibility, including nanoparticles, hydrogels, liposomes, micelles, dendrimer polymers, adenoviruses, lysozymes, and elastin-like polypeptides. These carriers have precise renal uptake, longer half-life, and targeted organ distribution, protecting and improving the efficacy of the drugs they carry. Additionally, attention should also be paid to the toxicity and solubility of the carriers. While the carriers mentioned above have been used in preclinical studies for targeted therapy of kidney diseases both in vivo and in vitro, extensive clinical trials are still needed to ensure the short-term and long-term effects of nano drugs in the human body. This review will discuss the advantages and limitations of nanoscale drug carrier materials in treating kidney diseases, provide a more comprehensive catalog of nanocarrier materials, and offer prospects for their drug-loading efficacy and clinical applications.

Citing Articles

Advances in medical devices using nanomaterials and nanotechnology: Innovation and regulatory science.

Lin C, Huang X, Xue Y, Jiang S, Chen C, Liu Y Bioact Mater. 2025; 48:353-369.

PMID: 40060145 PMC: 11889687. DOI: 10.1016/j.bioactmat.2025.02.017.

Recent advances in self-targeting natural product-based nanomedicines.

Liu H, Jin X, Liu S, Liu X, Pei X, Sun K J Nanobiotechnology. 2025; 23(1):31.

PMID: 39833846 PMC: 11749302. DOI: 10.1186/s12951-025-03092-9.

Nanoparticle-Based Drug Delivery for Vascular Applications.

Naskar A, Kilari S, Baranwal G, Kane J, Misra S Bioengineering (Basel). 2025; 11(12.

PMID: 39768040 PMC: 11673055. DOI: 10.3390/bioengineering11121222.

Multifunctional extracellular vesicles and edaravone-loaded scaffolds for kidney tissue regeneration by activating GDNF/RET pathway.

Lee S, Park J, Rhim W, Lee E, Lee S, Kim J Nano Converg. 2024; 11(1):43.

PMID: 39460807 PMC: 11512987. DOI: 10.1186/s40580-024-00450-5.

Dual-responsive renal injury cells targeting nanoparticles for vitamin E delivery to treat ischemia reperfusion-induced acute kidney injury.

Zhang J, Ren X, Nie Z, You Y, Zhu Y, Chen H J Nanobiotechnology. 2024; 22(1):626.

PMID: 39407248 PMC: 11481814. DOI: 10.1186/s12951-024-02894-7.

References

Dias A, da Silva Santos S, da Silva J, Parise-Filho R, Ferreira E, El Seoud O . Dendrimers in the context of nanomedicine. Int J Pharm. 2019; 573:118814. DOI: 10.1016/j.ijpharm.2019.118814. View

Ho T, Chang C, Chan H, Chung T, Shu C, Chuang K . Hydrogels: Properties and Applications in Biomedicine. Molecules. 2022; 27(9). PMC: 9104731. DOI: 10.3390/molecules27092902. View

Zuckerman J, Gale A, Wu P, Ma R, Davis M . siRNA delivery to the glomerular mesangium using polycationic cyclodextrin nanoparticles containing siRNA. Nucleic Acid Ther. 2015; 25(2):53-64. PMC: 4376487. DOI: 10.1089/nat.2014.0505. View

Chen Z, Li W, Shi L, Jiang L, Li M, Zhang C . Kidney-targeted astaxanthin natural antioxidant nanosystem for diabetic nephropathy therapy. Eur J Pharm Biopharm. 2020; 156:143-154. DOI: 10.1016/j.ejpb.2020.09.005. View

Gabizon A, Shmeeda H, Barenholz Y . Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet. 2003; 42(5):419-36. DOI: 10.2165/00003088-200342050-00002. View

Gu M, Lu L, Wei Q, Miao Z, Zhang H, Gao L . Improved oral bioavailability and anti-chronic renal failure activity of chrysophanol via mixed polymeric micelles. J Microencapsul. 2020; 38(1):47-60. DOI: 10.1080/02652048.2020.1849440. View

Liaw K, Zhang Z, Kannan S . Neuronanotechnology for brain regeneration. Adv Drug Deliv Rev. 2019; 148:3-18. DOI: 10.1016/j.addr.2019.04.004. View

Giovinazzo H, Kumar P, Sheikh A, Brooks K, Ivanovic M, Walsh M . Technetium Tc 99m sulfur colloid phenotypic probe for the pharmacokinetics and pharmacodynamics of PEGylated liposomal doxorubicin in women with ovarian cancer. Cancer Chemother Pharmacol. 2016; 77(3):565-73. DOI: 10.1007/s00280-015-2945-y. View

Williams R, Shah J, Ng B, Minton D, Gudas L, Park C . Mesoscale nanoparticles selectively target the renal proximal tubule epithelium. Nano Lett. 2015; 15(4):2358-64. PMC: 4518714. DOI: 10.1021/nl504610d. View

10.

Lin B, Ma Y, Wang J . Nano-Technological Approaches for Targeting Kidney Diseases With Focus on Diabetic Nephropathy: Recent Progress, and Future Perspectives. Front Bioeng Biotechnol. 2022; 10:870049. PMC: 9136139. DOI: 10.3389/fbioe.2022.870049. View

11.

Prabhakar U, Maeda H, Jain R, Sevick-Muraca E, Zamboni W, Farokhzad O . Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res. 2013; 73(8):2412-7. PMC: 3916009. DOI: 10.1158/0008-5472.CAN-12-4561. View

12.

Wang X, Lin Y, Zeng Y, Sun X, Gong T, Zhang Z . Effects of mycophenolic acid-glucosamine conjugates on the base of kidney targeted drug delivery. Int J Pharm. 2013; 456(1):223-34. DOI: 10.1016/j.ijpharm.2013.07.064. View

13.

Gao J, Liu R, Wu J, Liu Z, Li J, Zhou J . The use of chitosan based hydrogel for enhancing the therapeutic benefits of adipose-derived MSCs for acute kidney injury. Biomaterials. 2012; 33(14):3673-81. DOI: 10.1016/j.biomaterials.2012.01.061. View

14.

Pan X, Xie F, Xiao D, Zhou X, Xiao J . Design, Synthesis, and Renal Targeting of Methylprednisolone-Lysozyme. Int J Mol Sci. 2020; 21(6). PMC: 7139590. DOI: 10.3390/ijms21061922. View

15.

Castile J, Taylor K . Factors affecting the size distribution of liposomes produced by freeze-thaw extrusion. Int J Pharm. 1999; 188(1):87-95. DOI: 10.1016/s0378-5173(99)00207-0. View

16.

Bernhard S, Tibbitt M . Supramolecular engineering of hydrogels for drug delivery. Adv Drug Deliv Rev. 2021; 171:240-256. DOI: 10.1016/j.addr.2021.02.002. View

17.

Weers J, Metzheiser B, Taylor G, Warren S, Meers P, Perkins W . A gamma scintigraphy study to investigate lung deposition and clearance of inhaled amikacin-loaded liposomes in healthy male volunteers. J Aerosol Med Pulm Drug Deliv. 2009; 22(2):131-8. DOI: 10.1089/jamp.2008.0693. View

18.

Blanco E, Shen H, Ferrari M . Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015; 33(9):941-51. PMC: 4978509. DOI: 10.1038/nbt.3330. View

19.

Zhang C, Shang Y, Chen X, Midgley A, Wang Z, Zhu D . Supramolecular Nanofibers Containing Arginine-Glycine-Aspartate (RGD) Peptides Boost Therapeutic Efficacy of Extracellular Vesicles in Kidney Repair. ACS Nano. 2020; 14(9):12133-12147. DOI: 10.1021/acsnano.0c05681. View

20.

Huang D, Wu D . Biodegradable dendrimers for drug delivery. Mater Sci Eng C Mater Biol Appl. 2018; 90:713-727. DOI: 10.1016/j.msec.2018.03.002. View